About Superluminal Medicines:
Superluminal Medicines (Superluminal) is a generative biology and chemistry company revolutionizing the speed and accuracy of how small molecule medicines are created. The Company’s platform aims to create candidate-ready compounds with unprecedented speed using a combination of deep biology, computational and medicinal chemistry, machine learning, and proprietary big data infrastructure. We are expanding the team of talented scientists who seek to build the future of small molecule drug discovery with creativity and innovation.
About the Role:
Superluminal Medicines, Inc. is seeking a highly motivated and collaborative receptor pharmacologist to join the biology team. Reporting to the Head of Biology, the successful candidate will work collaboratively with the broader research team to provide deep mechanistic profiling of our lead molecules. The company is a target and biology-first drug discovery organization that applies artificial intelligence and machine learning (AI/ML) methods to common drug development bottlenecks while paying close attention to the seamless integration of biology, chemistry, and computation. This is a unique and exciting opportunity to build and grow a fruitful career with the company, apply your expertise to solve real world problems and leave a positive impact, advance the state of the practice of drug discovery and development, and address the unmet healthcare needs and help patients worldwide. At Superluminal we provide an environment where scientists at all levels can learn, grow, contribute their innovative ideas to have a direct impact on moving molecules to the clinic.
Roles and responsibilities:
- Develop, optimize and conduct biophysical assays against GPCR-based targets to gain deep mechanistic understanding of our lead molecules that may include orthosteric, allosteric and bitopic ligands.
- Establish cell-based functional assays and biochemical binding assays (fluorescent based) and design experiments to provide molecular profiling of lead molecules at steady state and their kinetic properties.
- Develop and maintain automated workflows, including liquid handling systems (Echo, D300, Bravo Benchcel), plate-based assays, and other lab automation tools.
- Demonstrate a high level of initiative to design experiments and provide high quality data to support advancement of multiple programs
- Actively participate in cross-functional project teams, fostering collaboration and transparency.
- Contribute to an open, cooperative environment by exchanging ideas and best practices with team members.
- Ensure compliance with company established practices and procedures
Qualifications:
- Ph.D. in Pharmacology, Biochemistry, Biology, or related discipline with 0-2 years working experience in GPCR pharmacology or enzymology. Applicants with BS or MS degrees must demonstrate a minimum of 5-8 years of relevant working experience.
- High energy and strong work ethic with a can-do attitude.
- Strong theoretical and practical background in GPCR pharmacology, or enzymology, and small-molecule drug discovery is a must.
- Experience working with the Creoptix is a plus.
- Demonstrated technical proficiency in biochemical, cellular, and/or binding assays and the ability to ensure highest quality of data.
- Strong communication skills and the ability to work closely and effectively in a multidisciplinary team environment.
- Ability to work in a fast-paced environment and adapt to changes.
- Highly organized with the ability to multitask between unrelated tasks.
Equal Opportunity Statement:
Superluminal Medicines is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.
Top Skills
What We Do
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.
With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.
